Human Recombinant Soluble BLyS/BAFF

• Description:

  Human Recombinant Soluble BLyS/BAFF _x000D_ Catalog number: B2016980_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 50 µg_x000D_ Molecular Weight or Concentration: 43.7 kDa_x000D_ Supplied as: Powder_x000D_ Applications: a molecular tool for various biochemical applications_x000D_ Storage: -80°C_x000D_ Keywords: B Cell-activating Factor, B Lymphocyte Stimulator, BAFF, CD257, Dendritic Cell-derived TNF-like Molecule, DTL, TALL-1, THANK, TNF Ligand Superfamily Member 13B, TNF- and APOL-related Leukocyte Expressed Ligand 1, TNFSF13B, TNFSF20, ZTNF4_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Li X, Su K, Ji C, Szalai AJ, Wu J, Zhang Y, Zhou T, Kimberly RP, Edberg JC. Immune opsonins modulate BLyS/BAFF release in a receptor-specific fashion J Immunol. 2008 Jul 15;181(2):1012-8._x000D_ 2: Fourcade L, Sabourin-Poirier C, Perraud V, Faucher MC, Chagnon-Choquet J, Labbé AC, Alary M, Guédou F, Poudrier J, Roger M. Natural Immunity to HIV is associated with Low BLyS/BAFF levels and low frequencies of innate marginal zone like CD1c+ B-cells in the genital tract PLoS Pathog. 2019 Jun 7;15(6):e1007840._x000D_ 3: James JA, Guthridge JM, Chen H, Lu R, Bourn RL, Bean K, Munroe ME, Smith M, Chakravarty E, Baer AN, Noaiseh G, Parke A, Boyle K, Keyes-Elstein L, Coca A, Utset T, Genovese MC, Pascual V, Utz PJ, Holers VM, Deane KD, Sivils KL, Aberle T, Wallace DJ, McNamara J, Franchimont N, St Clair EW. Unique Sjögren's syndrome patient subsets defined by molecular features Rheumatology (Oxford). 2020 Apr 1;59(4):860-868._x000D_ 4: Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease Nature. 2000 Apr 27;404(6781):995-9._x000D_ 5: Goenka R, Scholz JL, Sindhava VJ, Cancro MP. New roles for the BLyS/BAFF family in antigen-experienced B cell niches Cytokine Growth Factor Rev. 2014 Apr;25(2):107-13._x000D_ 6: Cancro MP. The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii34-6._x000D_ 7: Stohl W. Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr Rheumatol Rep. 2012 Aug;14(4):303-9._x000D_ 8: Tarantino G, Marco VD, Petta S, Almasio PL, Barbaria F, Licata A, Bosco GL, Tripodo C, Stefano RD, Craxì A. Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection J Viral Hepat. 2009 Jun;16(6):397-405._x000D_ 9: La Cava A. Targeting the BLyS-APRIL signaling pathway in SLE Clin Immunol. 2013 Sep;148(3):322-7._x000D_ 10: Poudrier J, Soulas C, Chagnon-Choquet J, Burdo T, Autissier P, Oskar K, Williams KC, Roger M. High expression levels of BLyS/BAFF by blood dendritic cells and granulocytes are associated with B-cell dysregulation in SIV-infected rhesus macaques PLoS One. 2015 Jun 24;10(6):e0131513. _x000D_ _x000D_ Products Related to Human Recombinant Soluble BLyS/BAFF can be found at Proteins

• Short Description:

  Catalog Number: B2016980 (50 µg)

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height:

  0.5

• Height :

  0.5

• CAS Number:

  9000-83-3